Biotech Boulevard
Startups and Spinouts
GEN's Biotech Boulevard highlights new entrepreneurial biotech firms based all over the globe. These unique companies are developing breakthrough products that will expand and enhance the biotech industry.
Discover, invest, and collaborate with these industry leaders of tomorrow.
Explore Biotech Boulevard. It's paved with opportunities!
GEN's Biotech Boulevard
All  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z   0  1  2  3  4  5  6  7  8  9   
  • Base Pair Biotechnologies www.basepairbio.com

    Base Pair Biotechnologies is a spin-off of parent company BioTex, a developer of several molecular biology and diagnostic technologies. Scientists at Base Pair Bio have been studying aptamers and developing them on a research basis and offer these services commercially.

  • Bina Technologies www.binatechnologies.com

    Bina is the big data science platform for large scale secondary and tertiary genomic analysis. Bina uses big data and cloud technologies to process raw genetic data in order to help clinicians and researchers administer treatment based on an individual's unique DNA. Bina's mission is to accelerate personalized medicine using whole genome analysis. The company was founded in 2011 by a team of Stanford and Berkeley researchers, data scientists, bioinformaticians, and entrepreneurs.

  • BioLamina www.biolamina.com

    BioLamina is a rapidly expanding biotechnology company within the stem cell and cell differentitation fields. Started as recently as 2009, it is already acknowledged as one of Sweden’s 33 most promising young technology companies. BioLamina produces and sells high-quality human recombinant laminins that are the foundation on which cells grow in vivo – and most likely the optimal surface for stem cells, primary cells and cell differentiation in vitro.

  • BioMoti www.biomoti.com

    BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to increase efficacy whilst reducing side effects. MOTI1001 is BioMoti's lead Oncojan™ based ovarian cancer candidate. Oncojans are a new class of therapeutic microparticles that can target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.

  • BioTillion www.biotillion.com

    BioTillion is enhancing the way samples are tracked in low temperature biobanks using RFID technology. They enable real-time precision tracking of samples in situ.

  • Blueprint Medicines www.blueprintmedicines.com

    Blueprint Medicines is committed to improving the lives of cancer patients by transforming genomically-defined subsets of cancer from life-threatening diseases to manageable conditions. Blueprint Medicines is harnessing the potential of the cancer genomics revolution by rapidly translating emerging insights into impactful drug programs.

  • BlueSEQ www.blueseq.com

    BlueSEQ helps research labs, universities, hospitals, and genome centers around the world design and outsource next-generation sequencing projects. The company matches sequencing service needs with providers that have the right next-generation sequencing technology and expertise. BlueSEQ provides a neutral source of market and technical information to support optimal next-generation sequencing project design and service provider compatibility.

© 2012 Genetic Engineering & Biotechnology News. All Rights Reserved.
Back to www.genengnews.com